Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colitis, Ulcerative | 28 | 2025 | 800 | 3.390 |
Why?
|
| Pouchitis | 9 | 2025 | 57 | 2.140 |
Why?
|
| Crohn Disease | 15 | 2025 | 808 | 1.760 |
Why?
|
| Proctocolectomy, Restorative | 8 | 2025 | 115 | 1.540 |
Why?
|
| Colonic Pouches | 8 | 2025 | 97 | 1.440 |
Why?
|
| Inflammatory Bowel Diseases | 11 | 2025 | 646 | 1.200 |
Why?
|
| Ustekinumab | 2 | 2020 | 52 | 0.720 |
Why?
|
| Gastrointestinal Agents | 5 | 2025 | 181 | 0.610 |
Why?
|
| Capsule Endoscopes | 1 | 2017 | 5 | 0.520 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2025 | 1001 | 0.520 |
Why?
|
| Ileal Neoplasms | 1 | 2017 | 9 | 0.520 |
Why?
|
| Dysbiosis | 2 | 2016 | 91 | 0.500 |
Why?
|
| Foreign Bodies | 1 | 2017 | 63 | 0.490 |
Why?
|
| Transcriptome | 2 | 2025 | 762 | 0.490 |
Why?
|
| Intestinal Mucosa | 4 | 2019 | 824 | 0.410 |
Why?
|
| Microbiota | 3 | 2016 | 425 | 0.400 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 249 | 0.390 |
Why?
|
| Remission Induction | 9 | 2025 | 738 | 0.390 |
Why?
|
| Retrospective Studies | 23 | 2025 | 10164 | 0.390 |
Why?
|
| Maintenance Chemotherapy | 2 | 2025 | 91 | 0.370 |
Why?
|
| Intestines | 2 | 2016 | 432 | 0.360 |
Why?
|
| Colitis | 3 | 2021 | 261 | 0.360 |
Why?
|
| Colon | 6 | 2025 | 540 | 0.340 |
Why?
|
| Biological Products | 2 | 2025 | 178 | 0.330 |
Why?
|
| Autophagy | 1 | 2012 | 172 | 0.320 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1173 | 0.310 |
Why?
|
| Adipose Tissue | 1 | 2012 | 270 | 0.310 |
Why?
|
| Treatment Outcome | 14 | 2025 | 9099 | 0.310 |
Why?
|
| Humans | 44 | 2025 | 93515 | 0.300 |
Why?
|
| Ileum | 5 | 2025 | 167 | 0.300 |
Why?
|
| Adult | 22 | 2025 | 27918 | 0.290 |
Why?
|
| Postoperative Complications | 7 | 2025 | 2562 | 0.280 |
Why?
|
| Cyclosporine | 2 | 2019 | 241 | 0.270 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2025 | 42 | 0.270 |
Why?
|
| Male | 25 | 2025 | 44557 | 0.260 |
Why?
|
| Inflammation | 6 | 2023 | 1050 | 0.250 |
Why?
|
| Interleukin-10 | 3 | 2017 | 163 | 0.250 |
Why?
|
| Bile Acids and Salts | 2 | 2024 | 77 | 0.250 |
Why?
|
| Prospective Studies | 8 | 2025 | 4560 | 0.240 |
Why?
|
| Immunosuppressive Agents | 3 | 2020 | 990 | 0.230 |
Why?
|
| Bacteroides fragilis | 2 | 2023 | 46 | 0.230 |
Why?
|
| Female | 21 | 2025 | 48702 | 0.210 |
Why?
|
| Oxadiazoles | 1 | 2023 | 37 | 0.200 |
Why?
|
| Indans | 1 | 2023 | 37 | 0.200 |
Why?
|
| Calcineurin Inhibitors | 2 | 2021 | 53 | 0.190 |
Why?
|
| Phenotype | 3 | 2025 | 2544 | 0.190 |
Why?
|
| Ulcer | 2 | 2022 | 38 | 0.190 |
Why?
|
| Tertiary Care Centers | 2 | 2025 | 129 | 0.190 |
Why?
|
| Gastrointestinal Tract | 2 | 2015 | 195 | 0.190 |
Why?
|
| Enterocolitis | 1 | 2022 | 13 | 0.180 |
Why?
|
| Infliximab | 2 | 2020 | 162 | 0.180 |
Why?
|
| Steroids | 2 | 2020 | 168 | 0.180 |
Why?
|
| Opportunistic Infections | 1 | 2022 | 57 | 0.180 |
Why?
|
| Recurrence | 6 | 2021 | 1190 | 0.180 |
Why?
|
| Treatment Failure | 2 | 2019 | 292 | 0.180 |
Why?
|
| Piperidines | 2 | 2022 | 165 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2022 | 111 | 0.170 |
Why?
|
| Colonic Diseases | 1 | 2021 | 59 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 555 | 0.160 |
Why?
|
| Middle Aged | 15 | 2025 | 27573 | 0.160 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2020 | 20 | 0.160 |
Why?
|
| Surgical Stomas | 1 | 2020 | 22 | 0.160 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2020 | 26 | 0.160 |
Why?
|
| Vitamin D Deficiency | 1 | 2021 | 107 | 0.150 |
Why?
|
| Aspirin | 1 | 2021 | 167 | 0.150 |
Why?
|
| Drug Substitution | 1 | 2019 | 28 | 0.150 |
Why?
|
| Drug Resistance | 1 | 2019 | 233 | 0.150 |
Why?
|
| Severity of Illness Index | 6 | 2020 | 1917 | 0.150 |
Why?
|
| Ileal Diseases | 1 | 2019 | 25 | 0.150 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 146 | 0.150 |
Why?
|
| Follow-Up Studies | 5 | 2025 | 3830 | 0.140 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2019 | 29 | 0.140 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2019 | 160 | 0.140 |
Why?
|
| Pyrroles | 1 | 2019 | 165 | 0.140 |
Why?
|
| Histocytochemistry | 1 | 2017 | 125 | 0.130 |
Why?
|
| Secondary Prevention | 1 | 2018 | 175 | 0.130 |
Why?
|
| Radiography, Abdominal | 1 | 2017 | 63 | 0.130 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2017 | 117 | 0.130 |
Why?
|
| Microscopy | 1 | 2017 | 89 | 0.130 |
Why?
|
| Anastomosis, Surgical | 3 | 2025 | 280 | 0.120 |
Why?
|
| Bacteroides | 1 | 2016 | 35 | 0.120 |
Why?
|
| Pyrimidines | 1 | 2019 | 384 | 0.120 |
Why?
|
| Gastrointestinal Motility | 1 | 2016 | 26 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2019 | 960 | 0.120 |
Why?
|
| Colectomy | 3 | 2025 | 192 | 0.120 |
Why?
|
| Clostridium Infections | 1 | 2018 | 128 | 0.120 |
Why?
|
| Genome, Bacterial | 1 | 2016 | 142 | 0.120 |
Why?
|
| Administration, Rectal | 1 | 2015 | 13 | 0.120 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 91 | 0.110 |
Why?
|
| Mucin-2 | 1 | 2015 | 12 | 0.110 |
Why?
|
| C-Reactive Protein | 3 | 2023 | 204 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 237 | 0.110 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 240 | 0.110 |
Why?
|
| Disease Progression | 2 | 2019 | 1531 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 339 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 836 | 0.100 |
Why?
|
| Young Adult | 6 | 2025 | 6930 | 0.100 |
Why?
|
| Metagenome | 1 | 2014 | 116 | 0.100 |
Why?
|
| Dexamethasone | 1 | 2015 | 312 | 0.100 |
Why?
|
| Immune System | 1 | 2014 | 101 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2022 | 3054 | 0.100 |
Why?
|
| Colonoscopy | 3 | 2019 | 303 | 0.090 |
Why?
|
| Risk Factors | 5 | 2025 | 5899 | 0.090 |
Why?
|
| Autophagy-Related Proteins | 1 | 2012 | 23 | 0.090 |
Why?
|
| Beclin-1 | 1 | 2012 | 15 | 0.090 |
Why?
|
| Endoscopy | 3 | 2021 | 366 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 201 | 0.090 |
Why?
|
| Leukocyte L1 Antigen Complex | 2 | 2023 | 50 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 185 | 0.090 |
Why?
|
| Genome | 1 | 2014 | 407 | 0.090 |
Why?
|
| Fatty Acids, Volatile | 1 | 2011 | 35 | 0.080 |
Why?
|
| Dialysis Solutions | 1 | 1990 | 7 | 0.080 |
Why?
|
| Lactates | 1 | 1990 | 36 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 76 | 0.080 |
Why?
|
| Butyrates | 1 | 2011 | 56 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2016 | 1415 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2012 | 663 | 0.070 |
Why?
|
| Biopsy | 1 | 2012 | 1175 | 0.070 |
Why?
|
| Postoperative Period | 2 | 2021 | 315 | 0.070 |
Why?
|
| Aged | 4 | 2020 | 20434 | 0.070 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2015 | 590 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 829 | 0.070 |
Why?
|
| Inpatients | 2 | 2021 | 345 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 1990 | 350 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2585 | 0.060 |
Why?
|
| Hemodynamics | 1 | 1990 | 713 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2022 | 894 | 0.060 |
Why?
|
| Propensity Score | 2 | 2018 | 178 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2012 | 2026 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 579 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2011 | 580 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2012 | 1264 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2020 | 688 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1338 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 2465 | 0.060 |
Why?
|
| Enterocytes | 1 | 2025 | 27 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 3435 | 0.050 |
Why?
|
| Prognosis | 2 | 2025 | 3911 | 0.050 |
Why?
|
| Amines | 1 | 2024 | 31 | 0.050 |
Why?
|
| Amides | 1 | 2024 | 54 | 0.050 |
Why?
|
| Bile | 1 | 2023 | 60 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2025 | 1518 | 0.050 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2024 | 86 | 0.050 |
Why?
|
| Catalysis | 1 | 2024 | 216 | 0.050 |
Why?
|
| Amino Acids | 1 | 2024 | 249 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2023 | 176 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 71 | 0.040 |
Why?
|
| Osteonectin | 1 | 2022 | 22 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2017 | 2121 | 0.040 |
Why?
|
| Ostomy | 1 | 2020 | 15 | 0.040 |
Why?
|
| Time Factors | 2 | 2019 | 5410 | 0.040 |
Why?
|
| Vitamin D | 1 | 2021 | 272 | 0.040 |
Why?
|
| Prednisolone | 1 | 2018 | 37 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 212 | 0.030 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2017 | 16 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 2017 | 50 | 0.030 |
Why?
|
| Dextran Sulfate | 1 | 2017 | 70 | 0.030 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2017 | 70 | 0.030 |
Why?
|
| Acute Disease | 1 | 2019 | 841 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 133 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 657 | 0.030 |
Why?
|
| Immunity, Mucosal | 1 | 2017 | 71 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2017 | 123 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 172 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 96 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 876 | 0.030 |
Why?
|
| Medical Records | 1 | 2017 | 121 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2018 | 193 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2016 | 82 | 0.030 |
Why?
|
| Tight Junctions | 1 | 2017 | 153 | 0.030 |
Why?
|
| Metagenomics | 1 | 2016 | 100 | 0.030 |
Why?
|
| Illinois | 1 | 2017 | 520 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1931 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2015 | 146 | 0.030 |
Why?
|
| Homeostasis | 1 | 2017 | 460 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2017 | 1133 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2017 | 337 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 367 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2015 | 232 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2015 | 259 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 1395 | 0.030 |
Why?
|
| Hospitalization | 1 | 2019 | 937 | 0.030 |
Why?
|
| Chicago | 1 | 2018 | 1464 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 3147 | 0.020 |
Why?
|
| Feces | 1 | 2015 | 360 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1161 | 0.020 |
Why?
|
| Animals | 3 | 2017 | 28155 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2850 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 353 | 0.020 |
Why?
|
| Mice | 2 | 2016 | 12269 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 2441 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1847 | 0.020 |
Why?
|
| Child | 1 | 2022 | 7355 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 1990 | 38 | 0.020 |
Why?
|
| Bicarbonates | 1 | 1990 | 58 | 0.020 |
Why?
|
| Acetates | 1 | 1990 | 60 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2495 | 0.020 |
Why?
|
| Phosphorus | 1 | 1990 | 119 | 0.020 |
Why?
|
| Lactic Acid | 1 | 1990 | 104 | 0.020 |
Why?
|
| Potassium | 1 | 1990 | 232 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 1028 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 3502 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 1990 | 1729 | 0.020 |
Why?
|
| Blood Pressure | 1 | 1990 | 896 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 9606 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 1990 | 429 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2011 | 1741 | 0.010 |
Why?
|